ArticleJornal brasileiro de nefrologia
Serum and urinary biomarkers in lupus nephritis: do suPAR and VEGF play a role?
Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum Concentrations of Vascular Endothelial Growth Factor in Polish Patients with Systemic Lupus Erythematosus Are Associated with Cardiovascular Risk and Autoantibody Profiles.Journal of clinical medicine · 2025Article
- Biomarkers in lupus nephritis: current challenges and future perspectives.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe extent, activity, and effects of renal involvement in systemic lupus erythematosus are conditions difficult to diagnose and a renal biopsy is usually required for such purpose. Non-invasive methods are then of high interest to better understand lupus nephritis (LN) features and prognosis. We have evaluated VEGF and suPAR levels as non-invasive biomarkers of disease activity in LN.
methodsThis cross-sectional study enrolled patients with LN aged 18 years or older of both genders who were assisted at the Outpatient Clinic of Glomerular Diseases of the Division of Nephrology of the Federal University of São Paulo (UNIFESP). Clinical renal histopathological characteristics, routine laboratory test profiles, and serum and urinary suPAR and serum VEGF of patients with LN were evaluated.
resultsThe sample consisted of 51 patients with LN, most of them females (88.2%), white (51.0%) with a mean age of 36.1 years (18 to 65 years), and a median disease duration of 2.5 years (1 month to 32 years). A positive correlation of urinary suPAR with SLEDAI-2K scores and hematuria was found. No significant correlation was found between serum VEGF and serum and urinary suPAR and proteinuria, serum creatinine, and urinary protein/creatinine ratio.
conclusionsSerum suPAR and VEGF levels were not indicative of renal or general SLE activity, but our data suggest that urinary suPAR may be a useful biomarker of such conditions, as its levels have been shown to correlate with the presence of hematuria and with higher SLEDAI-2K scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.